Skin Cancer

P3, N=360, Recruiting, Immatics US, Inc. | N=96 --> 360

The in vivo study showed significant reductions in myeloperoxidase levels and in UVB-induced 4-HNE and COX-2 protein levels. The research highlights the potential of Mn-NG-Nio for targeting skin cancer cells, reducing UVB-induced inflammation and oxidative stress.

A central thesis of this review is that these six contextual determinants establish a framework for understanding receptor pleiotropy. Furthermore, while targeting Plexin-B signaling shows therapeutic promise (eg, pepinemab in clinical trials), indiscriminate inhibition risks abrogating tumor-suppressive functions and perturbing immune microenvironment homeostasis, underscoring the necessity for biomarker-driven stratification to prevent paradoxical oncogenic consequences.

P=N/A, N=350, Not yet recruiting, Caja Costarricense de Seguro Social

P2, N=100, Active, not recruiting, Iovance Biotherapeutics, Inc. | Recruiting --> Active, not recruiting

This study provides important insights into the relationship between CRP levels and the risk of incident HF in cancer survivors. Future research should investigate whether interventions focused on reduction of inflammation could potentially decrease risk of HF in cancer survivors.

In vivo studies demonstrated that combination therapy reduced tumor volume without causing systemic toxicity, accompanied by decreased proliferation markers (PCNA and Ki-67), increased apoptotic marker (cleaved caspase-3), and decreased B7-H3 expression in tumor tissues. These results suggest that JI-CJ002 may enhance the antitumor activity of dabrafenib, accompanied by modulation of oncogenic pathways.

Additionally, we critically assess the therapeutic potential of targeting this switch, emphasizing how drugs that either inhibit or promote autophagy can work together with arsenic trioxide (ATO) to combat drug resistance in solid tumors such as glioblastoma and ovarian cancer. By shifting from simple descriptions to a detailed mechanistic and contextual understanding, this review offers a valuable guide for future research aiming to harness the autophagy switch for cancer prevention and personalized treatment.

P2, N=135, Not yet recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Initiation date: Feb 2026 --> Jun 2026

Our study reveals that the PKM2/HIF-1α axis upregulates glucose-serine metabolism to induce M2 polarization of TAMs and drive melanoma progression. Targeting this metabolic axis thus holds promise as a novel therapeutic strategy for melanoma patients.

P3, N=96, Recruiting, Immatics US, Inc.

P=N/A, N=296, Active, not recruiting, Herlev and Gentofte Hospital